LI
PACB icon

Louisbourg Investments’s Pacific Biosciences PACB Stock Holding History

Louisbourg Investments’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.51K Sell
900
-1,000
-53% -$1.45K ﹤0.01% 197
2026
Q1 		$2.51K Hold
1,900
– – ﹤0.01% 195
2025
Q4 		$3.55K Buy
+1,900
New +$3.65K ﹤0.01% 186

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
BLAM
Bourne Lent Asset Management Pawling, New York $289M AUM 30.86% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CAM
Carret Asset Management New York $1.14B AUM 35.33% 1-Year Est. Return

Louisbourg Investments's PACB Position: Q2 2026 in Review

Louisbourg Investments reduced its Pacific Biosciences (PACB) stake by 53% in Q2 2026, selling an estimated $1.45K and leaving 900 shares worth $1.51K. The position accounts for ﹤0.01% of the portfolio, ranked #197.

Louisbourg Investments first reported a position in PACB in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.55K in Q4 2025. 107 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Louisbourg Investments held 900 shares of Pacific Biosciences worth $1.51K as of Q2 2026.
  • Louisbourg Investments sold 1,000 Pacific Biosciences shares in Q2 2026, an estimated $1.45K.
  • Pacific Biosciences made up ﹤0.01% of Louisbourg Investments's portfolio in Q2 2026, its #197 holding.
  • Louisbourg Investments first reported a position in Pacific Biosciences in Q4 2025 and has held it in 3 quarters since.
  • Louisbourg Investments's Pacific Biosciences position peaked at $3.55K in Q4 2025.
  • 107 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Louisbourg Investments's 13F filing for Q2 2026, filed 23 Jul 2026.